Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor γδ T-Cell Infusion for AML After alloHCT
NCT05015426Phase 1Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2022
- Primary completion
- Aug 2025
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label trial of gamma delta T-cell infusion in acute myeloid leukemia (AML) (5 arms), sponsored by Moffitt Cancer Center. Primary endpoints: Maximum Tolerated Dose at 12 months and Leukemia Free Survival at 12 months. Started Mar 2022; status: active, not recruiting.
02
Drugs
gamma delta T-cell infusion
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05015426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05015426.